Literature DB >> 3792361

Assessment of radiotherapeutic effects on experimental tumors using 18F-2-fluoro-2-deoxy-D-glucose.

Y Abe, T Matsuzawa, T Fujiwara, H Fukuda, M Itoh, K Yamada, K Yamaguchi, T Sato, T Ido.   

Abstract

The purpose of this study is to evaluate the effect of tumor volume and radiotherapy on the uptake of 18F-2-fluoro-2-deoxy-D-glucose (18FDG). The tumor models used were mouse mammary carcinoma MM48, FM3A, and rat hepatoma AH109A. Results were expressed as an 18FDG uptake ratio. This was the ratio of irradiated tumor uptake of 18FDG to unirradiated tumor uptake. The total tumor uptake was expressed as 18FDG uptake ratio multiplied by relative tumor volume. Following 20 Gy irradiation of the radioresistant tumor (MM48), the 18FDG uptake ratio was found to be unchanged, whereas in radiosensitive tumors (FM3A) the 18FDG uptake ratio was 0.37, the relative tumor volume was 0.31, and the calculated total tumor uptake was 0.11 on the eighth day after irradiation. The total tumor uptake was lower than the relative tumor volume. AH109A began to regrow after ten Gy irradiation, accompanied by elevated uptake of 18FDG on the seventh day. These results suggest that the 18FDG uptake by tumor is a good marker of radiotherapeutic effects as well as relapses of cancers and is more sensitive than morphological methods.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3792361     DOI: 10.1007/bf00263812

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  5 in total

1.  Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography.

Authors:  G Di Chiro; R L DeLaPaz; R A Brooks; L Sokoloff; P L Kornblith; B H Smith; N J Patronas; C V Kufta; R M Kessler; G S Johnston; R G Manning; A P Wolf
Journal:  Neurology       Date:  1982-12       Impact factor: 9.910

2.  Experimental study for cancer diagnosis with positron-labeled fluorinated glucose analogs: [18F]-2-fluoro-2-deoxy-D-mannose: a new tracer for cancer detection.

Authors:  H Fukuda; T Matsuzawa; Y Abe; S Endo; K Yamada; K Kubota; J Hatazawa; T Sato; M Ito; T Takahashi; R Iwata; T Ido
Journal:  Eur J Nucl Med       Date:  1982

3.  Increased accumulation of 2-deoxy-2-[18F]Fluoro-D-glucose in liver metastases from colon carcinoma.

Authors:  Y Yonekura; R S Benua; A B Brill; P Som; S D Yeh; N E Kemeny; J S Fowler; R R MacGregor; R Stamm; D R Christman; A P Wolf
Journal:  J Nucl Med       Date:  1982-12       Impact factor: 10.057

4.  A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection.

Authors:  P Som; H L Atkins; D Bandoypadhyay; J S Fowler; R R MacGregor; K Matsui; Z H Oster; D F Sacker; C Y Shiue; H Turner; C N Wan; A P Wolf; S V Zabinski
Journal:  J Nucl Med       Date:  1980-07       Impact factor: 10.057

5.  Uptake of gallium-67 citrate and [2-3H]deoxyglucose in the tumor model, following chemotherapy and radiotherapy.

Authors:  G Iosilevsky; D Front; L Bettman; R Hardoff; Y Ben-Arieh
Journal:  J Nucl Med       Date:  1985-03       Impact factor: 10.057

  5 in total
  10 in total

1.  Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future.

Authors:  H Minn; R Paul
Journal:  Eur J Nucl Med       Date:  1992

2.  A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma.

Authors:  Y Ichiya; Y Kuwabara; M Sasaki; T Yoshida; J Omagari; Y Akashi; A Kawashima; T Fukumura; K Masuda
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

Review 3.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

Review 4.  Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?

Authors:  C S Brock; S R Meikle; P Price
Journal:  Eur J Nucl Med       Date:  1997-06

5.  Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers.

Authors:  Craig J Galbán; Mahaveer S Bhojani; Kuei C Lee; Charles R Meyer; Marcian E Van Dort; Kyle K Kuszpit; Robert A Koeppe; Rajesh Ranga; Bradford A Moffat; Timothy D Johnson; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 12.531

6.  Peripheral benzodiazepine receptors and glucose metabolism in human gliomas.

Authors:  C Ferrarese; C Pierpaoli; I Linfante; R H Bobo; B Guthrie; C Kufta; M O Duhaney; J Melisi; M J Fulham
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer.

Authors:  H Minn; I Soini
Journal:  Eur J Nucl Med       Date:  1989

8.  Metabolic changes of glioma following chemotherapy: an experimental study using four PET tracers.

Authors:  K Sato; M Kameyama; K Ishiwata; R Katakura; T Yoshimoto
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

9.  PET/CT Is Complementary to Fine-Needle Aspiration Cytology in Assessment of Irradiated Neck in Head and Neck Cancers.

Authors:  R C L Chan; Y W Chan
Journal:  Surg Res Pract       Date:  2014-05-18

10.  F-18-FDG and C-11-Choline Positron Emission Tomography in Human Esophago-Gastric Cancer: Prediction of Response to Therapy.

Authors:  Stuart Suttie; Dympna McAteer; Margaret Sheehan; Marianne Nicolson; Lutz Schweiger; Solveig Hammonds; Timothy Smith; Andrew Welch; Kenneth Park
Journal:  World J Oncol       Date:  2010-04-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.